Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women

Completed · Phase 4

Conditions studied: Urinary Incontinence

In brief

The purpose of the study is to assess the impact of treatment with tolterodine ER versus placebo on Urgency Urinary Incontinence in sexually active women with OAB symptoms.

Key facts

Study ID

NCT00143481

Run by

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

People needed

400

Starts

2005-03-01

Last updated by the study team

2021-01-27

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Female outpatients 18 years or older.
• Overactive bladder symptoms (subject-reported) for greater than or equal to 3 months.
• Currently sexually active with a male partner.

You may not qualify if…

• Diagnosed or suspected interstitial cystitis, uninvestigated hematuria, urogenital cancer, and interstitial or external radiation to the pelvis or external genitalia or clinically significant bladder outlet obstruction.
• Symptoms of incontinence being predominately stress urinary incontinence as determined by the investigator.
• Treated with antimuscarinic/ anticholinergic medication, for any reason including OAB, within the last 3 months or are expected to start therapy during the study treatment period.
• Any drug for urgency urinary incontinence (UUI) initiated within the past 3 months prior to Visit 1, with the exception of estrogen (topical or systemic) as long as treatment is not initiated within 4 weeks prior to Visit 1 (screening)

Where it is running

• Pfizer Investigational Site — Phoenix, Arizona, United States
• Pfizer Investigational Site — Little Rock, Arkansas, United States
• Pfizer Investigational Site — Berkeley, California, United States
• Pfizer Investigational Site — Oakland, California, United States
• Pfizer Investigational Site — San Diego, California, United States
• Pfizer Investigational Site — San Francisco, California, United States
• Pfizer Investigational Site — Santa Rosa, California, United States
• Pfizer Investigational Site — Denver, Colorado, United States
• Pfizer Investigational Site — Denver, Colorado, United States
• Pfizer Investigational Site — Lakewood, Colorado, United States
• Pfizer Investigational Site — Farmington, Connecticut, United States
• Pfizer Investigational Site — West Hartford, Connecticut, United States
• Pfizer Investigational Site — Clearwater, Florida, United States
• Pfizer Investigational Site — Leesburg, Florida, United States
• Pfizer Investigational Site — Miami, Florida, United States
• Pfizer Investigational Site — Pembroke Pines, Florida, United States
• Pfizer Investigational Site — West Palm Beach, Florida, United States
• Pfizer Investigational Site — Weston, Florida, United States
• Pfizer Investigational Site — Alpharetta, Georgia, United States
• Pfizer Investigational Site — Evansville, Indiana, United States
• Pfizer Investigational Site — Newburgh, Indiana, United States
• Pfizer Investigational Site — South Bend, Indiana, United States
• Pfizer Investigational Site — Baton Rouge, Louisiana, United States
• Pfizer Investigational Site — Metairie, Louisiana, United States
• Pfizer Investigational Site — Chandler, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.